Clinical Trial Update: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This document reports an ongoing Phase 1/2 clinical trial evaluating IMGN632 as a monotherapy or in combination with venetoclax and/or azacitidine for adults wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• IMGN632
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING